NEOGEN CORP (NEOG): Results of Operations and Financial Condition
NEOGEN CORP (NEOG) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 neog-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Neogen Reports Fourth Quarter and Full Fiscal Year 2026 Financial Results Delivered Strong Core Growth in Q4 FY26 with Food Safety Core Growth Highest Since FY23 • Fiscal fourth quarter 2026 revenue of $225.3 million represen
How this was made
The 30-second read
Why it matters
The combination of quantified profitability improvement (Adjusted EBITDA margin 20.2% in Q4), segment-level growth (Food Safety core growth highest since FY23), and explicit Petrifilm manufacturing milestones can drive repricing of near-term earnings expectations and execution risk.
Market read
Actionable for traders because it is a first-hand earnings-and-guidance disclosure with operational milestone dates that can affect forward estimates.
What to watch
The filing references supply challenges resolution and a manufacturing transition; traders may need to watch for any guidance details and execution risk around the Nov 2026 transition window.
Background
This is an SEC Form 8-K (Item 2.02) reporting Neogen’s fiscal Q4 and full fiscal year 2026 financial results and providing FY27 guidance.
Ticker impact
Neogen filed an 8-K with FY26 results and provided FY27 revenue and Adjusted EBITDA guidance, including Petrifilm manufacturing transition timing.
Moderate positive bias for the next trading session as guidance and operational milestones reduce uncertainty, though Animal Safety weakness and FY26 revenue decline may cap upside.
The filing includes multiple quantified financial metrics (revenue, adjusted EBITDA, margins) and explicit operational timing (validated Petrifilm SKU by end of Aug 2026, multi-quarter transition beginning Nov 2026) plus FY27 guidance, which are actionable for positioning.
Market effects
Food safety and animal health suppliers may see read-through on demand durability in Indicator Testing and Culture Media versus weaker Rodent/Insect categories.
International revenue was roughly flat to slightly up in FY26, suggesting global demand resilience rather than purely domestic strength.
Operational execution on key product lines (Petrifilm) can influence confidence in supply continuity for lab testing workflows.
Counterpoint
Despite core growth and margin improvement, total FY26 revenue declined and Animal Safety revenue fell year over year, implying the market may focus on whether FY27 guidance offsets segment softness.
Key entities
- companyNeogen Corporation
Reports FY26 Q4 and full-year results, provides FY27 guidance, and outlines Petrifilm manufacturing transition timing.
- productPetrifilm
Company expects to manufacture sellable product and begin a multi-quarter manufacturing transition starting November 2026.
